Clinicians praise the S8-SGTB appliance for accelerating outcomes, improving patient satisfaction, and offering a non-invasive solution for Class II malocclusions.
KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee's Mandibular Repositioning Technology and showcased its clinical applications, particularly the innovative S8-SGTB appliance for Class II skeletal malocclusions. Australian clinicians praised the device for its simultaneous orthopedic and orthodontic correction, shorter treatment duration, and patient-friendly design.
Dr. Knox Kim, Principal Dentist at Dental Clinic @ World Tower Sydney, shared:
"In the past, for treating Class II malocclusions in growing patients, we had to use twin-block appliances before starting aligner therapy. It took at least three to six months to see the improvement. But with Smartee, from my own experience, it only took about one or two weeks before the patient could notice the lower jaw was pushing forward. And when I show the patients and the patients' parents the before and after photos, they were very happy to see such a quick response and improvement."
Dr. Jenny J. Song from Blossom Dental Care added:
"Compared to traditional functional and fixed appliances, Smartee GS is intelligently designed to guide both mandible repositioning and teeth movement simultaneously. This not only reduces total treatment time but also improves the predictability of outcomes."
Dr. Sabrina Liu, a general dentist in Sydney, reflected:
"This seminar was eye-opening. The number of successful mandibular repositioning cases using Smartee GS aligners changed my perception of what clear aligners can achieve. I hope more dentists in Australia will learn about this technique to benefit their patients."
At the core of Smartee's Mandibular Repositioning Technology is S8-SGTB, a clear, non-invasive appliance designed to treat skeletal Class II discrepancies, minimizing the need for jaw surgeries or extractions. Engineered for both growing and adult patients, it integrates orthopedic and orthodontic functions in a single aligner-based solution.
Key features include:
- Simultaneous mandibular repositioning and dental alignment
- Anotomical occlusal splints and locking components for stable joint advancement
- Minimizing need for extractions or surgeries
- Discreet, comfortable design compared to bulky functional devices
The S8-SGTB represents Smartee's commitment to delivering clinically effective, patient-centered treatment paths for complex cases.
Learn more about Smartee Mandibular Repositioning, please visit https://www.smarteealigners.com/products/smartee-gs-mandibular-repositioning-aligners/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
TAIPEI, Dec. 31, 2025 /PRNewswire/ -- ARTERY Technology (Cayman) Corporation (Stock Code: 6907; hereinafter referred to as "ARTERY-KY"), a leading designer of 32-bit microcontrollers (MCUs), is scheduled to be listed on the Taipei Exchange (TPEx) under the Semiconductor Industry category in January 2026. The Company held its first pre-IPO investor conference on December 30 (Tuesday) at the Grand Hyatt Taipei, where it presented its competitive strengths and future business outlook to investors.
As a subsidiary of Faraday Technology, ARTERY-KY focuses on the development of high-end 32-bit MCUs. Leveraging ARM® Cortex®-M4 cores with an industry-leading maximum clock speed of up to 288 MHz, the Company delivers exceptional performance. In addition to successfully entering the supply chains of leading global brands, ARTERY-KY has established itself as a key contributor in the China market through localized technical advantages, serving as an important partner in regional supply chain transformation.
ARTERY-KY possesses comprehensive technical capabilities spanning core architecture design to application integration. Its end-market applications cover a wide range of fields, including industrial and motor control, consumer electronics, commercial applications, and vertical industries such as medical, IoT, communications, and automotive electronics. With strengths in high performance, low power consumption, superior integration, and high cost-effectiveness, the Company continues to expand into emerging applications such as drones, robotics, and edge AI, demonstrating strong market competitiveness and growth momentum.
In terms of financial performance, ARTERY-KY recorded revenue of NT$1.635 billion in 2024, representing a year-on-year increase of over 60%, with earnings per share (EPS) of NT$1.67. Revenue for the first three quarters of 2025 reached NT$1.234 billion, maintaining a high level and setting a new historical high for the same period, indicating that the Company has emerged from the inventory adjustment cycle. With continued optimization of its product mix, gross margin rebounded significantly to 33.84%. Net profit after tax for the first three quarters totaled NT$70.52 million, with basic EPS of NT$1.38, marking a 56% year-on-year increase and reflecting solid profitability. As multiple new application projects enter mass production and major customer orders continue to grow steadily, the market expects further optimization of the product portfolio in 2026, driving simultaneous growth in revenue and earnings.
Looking ahead, ARTERY-KY has outlined three major growth strategies. First, it will establish a comprehensive MCU foundation spanning M0 to M85 to build a highly compatible ecosystem. Second, it will expand its ASIC-based customized MCU services to help customers rapidly develop application-specific chips. Finally, the Company will aggressively pursue edge AI opportunities by collaborating with UMC and Faraday Technology, utilizing the most advanced 28-nanometer embedded Flash process to develop an intelligent inference platform. Through a strategy focused on breadth, depth, and forward-looking innovation, ARTERY-KY aims to fully activate its semiconductor growth engine.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Emerging MCU Force ARTERY-KY to Be Listed on TPEx in January 2026, Driving High-Performance Growth Through MCU, Customization, and Edge AI
